企業プロフィール
Enlivex Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- ENLV
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- Israel and listed in the U
株価パフォーマンス
1.47 USD (-2.00%)
終値
最終更新: 2026年8月21日
205M USD
時価総額
株価変動の要因
As of Aug 21, 2026, ENLV closed down 2.00% at $1.47. No new same-company headline was identified in the current news window.
企業概要
事業概要
Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.
所在地とセクター分類
Enlivex is headquartered in Israel and listed in the U.S. market. It sits in small-cap immunology biotechnology.
ビジネスモデルの特徴
The company depends on translational validation, early clinical progress, and capital support. Investors typically watch proof-of-concept data and whether the platform can create durable value.
バイオ業界での位置付け
Enlivex occupies a niche innate-immunity position within biotech. The stock is driven by whether macrophage reprogramming can become a meaningful therapeutic strategy.
今後のカタリスト
- Enlivex’s catalysts are Allocetra and its osteoarthritis / immunology programs, along with any update that clarifies whether the platform still has a viable path. The company remains data-sensitive.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。